A citation-based method for searching scientific literature

Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel, April W Armstrong, Georg Stingl, Alexa B Kimball, Herve Bachelez, Jashin J Wu, Jeffrey Crowley, Richard G Langley, Tomasz Blicharski, Carle Paul, Jean-Philippe Lacour, Stephen Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian Kotzin, Ajay Nirula. N Engl J Med 2015
Times Cited: 469







List of co-cited articles
1001 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
53

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
K A Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, R G Langley, J Cather, A B Gottlieb,[...]. Br J Dermatol 2016
264
41

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
232
39

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
444
38

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
530
38



Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
258
30

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
28

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li,[...]. Lancet 2008
27

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
791
23

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Alan Menter, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, Martin Kaul, Yihua Gu, Martin Okun,[...]. J Am Acad Dermatol 2008
618
22

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, Craig L Leonardi, Yves Poulin, Janice Drew, Luke Peterson, Catherine Arendt, Daniel Burge, Kristian Reich. J Am Acad Dermatol 2018
82
24

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Kim A Papp, Craig Leonardi, Alan Menter, Jean-Paul Ortonne, James G Krueger, Gregory Kricorian, Girish Aras, Juan Li, Chris B Russell, Elizabeth H Z Thompson,[...]. N Engl J Med 2012
706
20

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
345
20

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm,[...]. Br J Dermatol 2017
104
17

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Kenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C Prinz, Yasmine Wasfi, Shu Li, Yaung-Kaung Shen, Philippe Szapary, Bruce Randazzo, Kristian Reich. N Engl J Med 2015
201
16

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Christopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, Bei Zhou, Shu Li,[...]. N Engl J Med 2010
610
16

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Kim A Papp, Joseph F Merola, Alice B Gottlieb, Christopher E M Griffiths, Nancy Cross, Luke Peterson, Christopher Cioffi, Andrew Blauvelt. J Am Acad Dermatol 2018
94
17

Etanercept as monotherapy in patients with psoriasis.
Craig L Leonardi, Jerold L Powers, Robert T Matheson, Bernard S Goffe, Ralph Zitnik, Andrea Wang, Alice B Gottlieb. N Engl J Med 2003
879
15

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
A Blauvelt, J C Prinz, A B Gottlieb, K Kingo, H Sofen, M Ruer-Mulard, V Singh, R Pathan, C Papavassilis, S Cooper. Br J Dermatol 2015
218
15

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
K Papp, D Thaçi, K Reich, E Riedl, R G Langley, J G Krueger, A B Gottlieb, H Nakagawa, E P Bowman, A Mehta,[...]. Br J Dermatol 2015
178
15

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
108
15

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
182
15

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Alan Menter, Steven R Feldman, Gerald D Weinstein, Kim Papp, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Cynthia Arnold, Alice B Gottlieb. J Am Acad Dermatol 2007
345
14

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
K A Papp, S Tyring, M Lahfa, J Prinz, C E M Griffiths, A M Nakanishi, R Zitnik, P C M van de Kerkhof, Linda Melvin. Br J Dermatol 2005
520
14

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
C Paul, J-P Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, C Guindon, R You, C Papavassilis. J Eur Acad Dermatol Venereol 2015
201
14

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
April W Armstrong, Luis Puig, Avani Joshi, Martha Skup, David Williams, Junlong Li, Keith A Betts, Matthias Augustin. JAMA Dermatol 2020
57
24

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
49
28

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Alan Menter, Bruce E Strober, Daniel H Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W Armstrong, Cody Connor, Kelly M Cordoro, Dawn M R Davis,[...]. J Am Acad Dermatol 2019
236
14

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
Jerry Bagel, John Nia, Peter W Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Isabelle Gilloteau, Elisa Muscianisi,[...]. Dermatol Ther (Heidelb) 2018
36
38

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
926
14

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Mark Lebwohl, Andrew Blauvelt, Carle Paul, Howard Sofen, Jolanta Węgłowska, Vincent Piguet, Daniel Burge, Robert Rolleri, Janice Drew, Luke Peterson,[...]. J Am Acad Dermatol 2018
69
18

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Kenneth B Gordon, Richard G Langley, Craig Leonardi, Darryl Toth, M Alan Menter, Sewon Kang, Michael Heffernan, Bruce Miller, Regina Hamlin, Liberata Lim,[...]. J Am Acad Dermatol 2006
376
13

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams,[...]. Lancet 2019
100
13

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
551
13

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
J-H Saurat, G Stingl, L Dubertret, K Papp, R G Langley, J-P Ortonne, K Unnebrink, M Kaul, A Camez. Br J Dermatol 2008
515
13

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
Tsen-Fang Tsai, Ji-Chen Ho, Michael Song, Philippe Szapary, Cynthia Guzzo, Yuang-Kuang Shen, Shu Li, Kwang-Joong Kim, Tae-Yoon Kim, Jee-Ho Choi,[...]. J Dermatol Sci 2011
140
12

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
Stephan R Targan, Brian Feagan, Severine Vermeire, Remo Panaccione, Gil Y Melmed, Carol Landers, Dalin Li, Chris Russell, Richard Newmark, Nan Zhang,[...]. Am J Gastroenterol 2016
191
12

Psoriasis.
Wolf-Henning Boehncke, Michael P Schön. Lancet 2015
12

Psoriasis.
Jacqueline E Greb, Ari M Goldminz, James T Elder, Mark G Lebwohl, Dafna D Gladman, Jashin J Wu, Nehal N Mehta, Andrew Y Finlay, Alice B Gottlieb. Nat Rev Dis Primers 2016
304
11

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring,[...]. N Engl J Med 2017
270
11

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Kim Papp, Kristian Reich, Craig L Leonardi, Leon Kircik, Sergio Chimenti, Richard G B Langley, ChiaChi Hu, Randall M Stevens, Robert M Day, Kenneth B Gordon,[...]. J Am Acad Dermatol 2015
303
11

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan,[...]. N Engl J Med 2015
464
11


Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Kim Papp, Kenneth Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab G Girgis, Sudeep Kundu, Subhashis Banerjee. N Engl J Med 2018
149
11

Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
Mark G Lebwohl, Kim A Papp, Lauren B Marangell, John Koo, Andrew Blauvelt, Melinda Gooderham, Jashin J Wu, Shipra Rastogi, Susan Harris, Radhakrishnan Pillai,[...]. J Am Acad Dermatol 2018
81
13

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
102
11

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
Philip J Mease, Mark C Genovese, Maria W Greenwald, Christopher T Ritchlin, André D Beaulieu, Atul Deodhar, Richard Newmark, JingYuan Feng, Ngozi Erondu, Ajay Nirula. N Engl J Med 2014
266
10

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Mamitaro Ohtsuki, Hideki Fujita, Mitsunori Watanabe, Keiko Suzaki, Mary Flack, Xin Huang, Susumu Kitamura, Joaquin Valdes, Atsuyuki Igarashi. J Dermatol 2019
39
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.